About Us

Who are we?

The MotherToBaby CA, formerly known as the California Teratogen Information Service (CTIS) Pregnancy Health Information Line and Clinical Research Program, is a statewide service. Our goal is to promote healthy pregnancies through education and research.

What is Teratology?

Teratology is the study of birth defects caused by exposures during pregnancy.

What services do we provide?

Our service provides FREE information about the following exposures during pregnancy:

  • Over the Counter Medications
  • Prescription Medications
  • Vitamins/Supplements
  • Alcohol/Recreational Drugs
  • Vaccinations or Immunizations
  • Diseases or Infections
  • Chemicals
  • Pesticides
  • Occupational Exposures
  • Paternal Exposures

We also provide information about the effects of medications taken while breastfeeding.

This service is offered to the general public, including pregnant and breastfeeding women, women planning their pregnancy, fathers, physicians, and other health care providers. The information and counseling is provided in a non-directive, and non-judgmental manner.

How do I contact MotherToBaby CA?

To speak with a Teratogen Information Specialist about your questions call: 1-866-626-6847 from anywhere in North America, or email a counselor.

For general inquiries:

MotherToBaby CA
University of California, San Diego School of Medicine
Department of Pediatrics
9500 Gilman Drive #0828 La Jolla, CA 92093-0828
FAX: 858.246.1708
Email: ctispregnancy@ucsd.edu

MotherToBaby CA is an affiliate of the international Organization of Teratology Information Specialists (OTIS).

2 Responses to “About Us”

  1. Alice Feinstein CNM Reply August 9, 2011 at 8:26 pm

    Please advise: 7 week pregnant Mom takes Rizatriptan Benzoate for Migraines.
    Thank you.

  2. Mara, CTIS expert Reply August 12, 2011 at 9:29 pm

    Based on unpublished animal data, no increased risk of birth defects is expected with rizatriptan. However, human data is preferred for better prediction of human pregnancy effects. No pattern of birth defects to suggest cause and effect to a single agent was seen in a small study of women taking rizatriptan. Due to the limited human data, rizatriptan is not a preferred treatment during pregnancy for migraines.

    Of the triptans, sumatriptan has the most pregnancy data since it was the first one to be approved by the FDA and released in 1992. Available studies with sumatriptan have not also found not found a pattern of birth defects related to this medicine use. For example, a Swedish registry found no increase in birth defects in 658 infants exposed to sumatriptan at some point during their mother’s pregnancy.

    However, published articles differ on their opinions about purposeful use of sumatriptan during pregnancy. Some authors report that sumatriptan should be avoided due to theoretical concerns (vasoconstriction) while others point to the reassuring available pregnancy data for at least the first trimester. Use post first trimester is not well studied. One study in 2010 found a slight increase in maternal complications but not fetal complications with late sumatriptan use.

    If a nontriptan medicine has proven effective in the past for your client, plus has a good pregnancy safety profile, that would be an alternative option.

Leave a Reply

Comments posted here will be visible to those who visit this website; if you have a specific question for a MotherToBaby CA counselor, see our email an expert form.